Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EVMN vs REPL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 2–3 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: EVMN 3 – 1 REPL (2 Tie) Matrix Metrics: EVMN 2 – 3 REPL

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Replimune Group, Inc. (REPL) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas REPL carries 27.4/100 (SELL) at $21.41 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both EVMN (30.0/100 SELL) and REPL (27.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVMN vs REPL
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47
REPL NASDAQ
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$21.41
-2.19% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.08β · 100% Vol
Unified Composite Score
27.4 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.3% over 20 days), RSI 70
RSI-14: 69.6 · SMA20: $17.92 · SMA50: $14.89

6-Pillar Scorecard Institutional Category Breakdown (EVMN 3 – 1 REPL)

Columns: Metric · EVMN · REPL
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale REPL
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $315.5M $2.1B
3. Profitability & Quality EVMN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -69.5% -115.8%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$75M -$246M
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $181M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase SURGE BREAKOUT
Current IV / %ile 209.0% (53rd %ile) 220.4% (23rd %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVMN (2) vs REPL (3)
Institutional Metric EVMN REPL Criterion Row Edge
Market Capitalization
Scale
$315.5M $2.1B Larger Scale REPL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-69.5% -115.8% Higher ROE EVMN
52-Week Range Position
Momentum
8% ($5–$33) 90% ($2–$24) Stronger Trend REPL
Beta / 30D Volatility
Risk Regime
1.05β · 118% Vol 2.08β · 100% Vol Lower Realized Risk REPL
Unified Institutional Score
Composite Signal
30.0 / 100 (SELL) 27.4 / 100 (SELL) Higher Composite EVMN
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($52M Net Cash) -$246M ($181M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REPL +59.82 pp
EVMN: +37.33% · REPL: +97.15%
3M Horizon REPL +87.49 pp
EVMN: -50.07% · REPL: +37.42%
6M Horizon REPL +379.17 pp
EVMN: -69.02% · REPL: +310.15%
1Y Horizon REPL +199.45 pp
EVMN: -61.03% · REPL: +138.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVMN vs REPL. Trailing 12-month operating profitability (EVMN 0.0% vs REPL 0.0%) and valuation multiples (EVMN N/M vs REPL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EVMN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.5% · N/M
REPL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-115.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REPL BREAKOUT
98d in phase · OBV NEUTRAL
Current IV 220.4%
IV Percentile 23rd %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact REPL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
REPL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVMN vs REPL Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Replimune Group, Inc. (REPL) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas REPL carries 27.4/100 (SELL) at $21.41 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both EVMN (30.0/100 SELL) and REPL (27.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

REPL leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with REPL at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EVMN generates N/A in USD-normalized revenue versus N/A for REPL. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for REPL.

EVMN and REPL trade at balanced relative valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas REPL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus REPL (-115.8% ROE) capital efficiency.

In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, REPL carries 220.4% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (2.08β · 100% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.